Page 3 - Michael Klichinsky News Today

/PRNewswire/ -- Carisma Therapeutics Inc. (Carisma Therapeutics), a clinical stage biopharmaceutical company focused on discovering and developing innovative...

/PRNewswire/ -- Carisma Therapeutics Inc. (Carisma Therapeutics), a clinical stage biopharmaceutical company focused on discovering and developing innovative...

/PRNewswire/ -- Carisma Therapeutics, a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, will be...

Preliminary findings from Penn Medicine in an ongoing first-in-human clinical trial examining the safety, tolerability and feasibility of chimeric antigen recep

Preliminary findings from Penn Medicine in an ongoing first-in-human clinical trial examining the safety, tolerability and feasibility of chimeric antigen receptor macrophage (CAR-M) has helped to establish the viability of this innovative immunotherapy, which advances the trailblazing scientific discovery of CAR T cell therapy- also pioneered at Penn- for solid cancer tumors and offers a promising new strategy in the fight against cancer.

Share this article Share this article Allogeneic macrophage therapies may prove successful in providing a solution forged in cell therapy to a broader population of patients, further extending the potential benefits of CARISMAs CAR-Macrophage (CAR-M) platform beyond oncology and into other disease states with unmet clinical needs.   "The collaboration with Dr. Blazar marks the initiation of the development of allogeneic, universal donor derived monocyte and macrophage cell therapies at CARISMA...

CARISMA Therapeutics to Present Data at The American Association for Cancer Research Annual Meeting - First study evaluating CAR-macrophages in fully immunocompetent solid tumor mouse models shows significant tumor control, increased survival, and induction of anti-tumor immunity - New ultra-rapid, same-day CAR-monocyte manufacturing process may reduce "vein-to-vein" time News provided by Share this article Share this article PHILADELPHIA, April 9, 2021 /PRNewswire/ -- CARISMA Therapeutics Inc....

Share this article Share this article PHILADELPHIA, Jan. 7, 2021 /PRNewswire/ -- CARISMA Therapeutics Inc., a biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced today that it has completed its Series B equity financing providing for gross proceeds of $47 million, bringing CARISMAs total capital raised to nearly $109 million. The funding will be used to advance current pipeline and discovery programs, including the Phase I clinical trial of C...

Search jobs CAR-M: the Super Evolution of Macrophages to Fight Against Tumors Summary Macrophages are white blood cells that engulf and digest cellular debris, foreign substances, microbes, and cancer cells. Recently, scientists are exploring the method to make macrophage stronger, that is to give it a CAR. These CAR-M cells are expected to efficiently treat tumors. Author Name: Candy Swift Editor: Iris...